CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
corporation (the Company) issued a press release in connection
with its fiscal year ended December 31, 2016. A copy of the press
release is filed as Exhibit 99.1 to this Current Report on From
8-K and is incorporated into this Item 8.01 by reference.
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release, dated March 17, 2017
|
About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)
Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases. CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Recent Trading Information
CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) closed its last trading session up +0.63 at 5.73 with 3,019,997 shares trading hands.
